5TZC image
Entry Detail
PDB ID:
5TZC
Title:
Crystal Structure of human PDE2a in complex with (5S)-1-[(3-bromo-4-fluorophenyl)carbonyl]-3,3-difluoro-5-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}piperidine
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2016-11-21
Release Date:
2017-02-22
Method Details:
Experimental Method:
Resolution:
2.36 Å
R-Value Free:
0.24
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
P 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:cGMP-dependent 3',5'-cyclic phosphodiesterase
Chain IDs:A, B, C, D
Chain Length:344
Number of Molecules:4
Biological Source:Homo sapiens
Primary Citation
Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders.
J. Med. Chem. 60 2037 2051 (2017)
PMID: 28165743 DOI: 10.1021/acs.jmedchem.6b01793

Abstact

A series of potent and selective [1,2,4]triazolo[1,5-a]pyrimidine PDE2a inhibitors is reported. The design and improvement of the binding properties of this series was achieved using X-ray crystal structures in conjunction with careful analysis of electronic and structural requirements for the PDE2a enzyme. One of the lead compounds, compound 27 (DNS-8254), was identified as a potent and highly selective PDE2a enzyme inhibitor with favorable rat pharmacokinetic properties. Interestingly, the increased potency of compound 27 was facilitated by the formation of a halogen bond with the oxygen of Tyr827 present in the PDE2a active site. In vivo, compound 27 demonstrated significant memory enhancing effects in a rat model of novel object recognition. Taken together, these data suggest that compound 27 may be a useful tool to explore the pharmacology of selective PDE2a inhibition.

Legend

Protein

Chemical

Disease

Primary Citation of related structures